Princeton, NJ, February 24, 2023 ─ iQure Pharma Inc. (iQure), a US-based biotech company, is making significant progress in the development of its two assets, iQ-007, a novel anticonvulsant and analgesic compound, and iQ-008, a novel compound against neuropathic pain.
In the last few months, its lead compound iQ-007, has completed a set of critical experiments with two important results: increasing iQ-007’s excellent safety profile by establishing the lack of abuse potential and lack of genotoxicity and confirming additional favorable characteristics of the compound. These include a positive brain uptake based on the MDCK-MDR1 Permeability Assay, plasma protein binding in a series of species, and solubility experiments. In collaboration with researchers from the Jagiellonian University, a series of formulation and pharmacokinetic experiments were conducted to optimize the iQ-007 formulation. This will allow completion of the formulation development for the next set of experiments to continue on schedule. Initial formulation work was also completed for iQ-008, enabling further pharmacokinetic and efficacy studies as part of the NIH PSPP program.
“This is very good news and an important step in the continued development of iQ-007 and iQ-008 as promising therapeutics,” said iQure Chief Operating Officer Henk de Wilde. “With the new formulations under development, we can achieve the full potential of both compounds and maximize the benefit for future patients.”
About iQure Pharma
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at firstname.lastname@example.org.